Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Securities and Exchange Commission v. Aveo Pharmaceuticals, Inc. et al
Case Number:
1:16-cv-10607
Court:
Nature of Suit:
Judge:
Firms
Government Agencies
-
February 05, 2018
Ex-Aveo Exec Fights SEC Penalty, Says He's Learned Lesson
A former Aveo Pharmaceuticals Inc. executive continued to argue in Massachusetts federal court Monday that he should not have to pay a fine or be barred from leadership positions over the Securities and Exchange Commission's allegations that he deceived investors about Aveo's flagship kidney cancer drug, saying he had learned his lesson.
-
January 17, 2018
Ex-Aveo Exec Says SEC Exaggerated Role In Investor Fraud
Aveo Pharmaceuticals Inc.'s former chief medical officer told a Massachusetts federal court Tuesday that he shouldn't have to pay a fine or be barred from leadership positions because the U.S. Securities & Exchange Commission exaggerated his alleged role in deceiving investors about Aveo's kidney cancer drug, Tivo.
-
November 09, 2017
Ex-Aveo Exec's Penalty In SEC Deal Up To Magistrate Judge
A Massachusetts magistrate judge will decide whether Aveo Pharmaceuticals Inc.'s former chief medical officer should pay a civil penalty under a deal that would resolve the U.S. Securities and Exchange Commission's allegations that he hid from investors the Food and Drug Administration's concerns about its flagship kidney cancer drug.
-
March 29, 2016
Aveo Pays $4M To End SEC Claims It Misled Investors
Massachusetts-based biotechnology company Aveo Pharmaceuticals Inc. will pay $4 million to settle the U.S. Securities and Exchange Commission's allegations it hid from investors the Food and Drug Administration's concerns over its flagship kidney cancer drug, the SEC said Tuesday.
- ← Previous
- 1
- 2
- Next →